Bladder Disorders Clinical Trials

A listing of Bladder Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 353 clinical trials
Featured trial
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors

This is a multicenter, open-label, dose-escalation/dose-expansion Phase 1 clinical study to investigate the safety, tolerability, PK profile, pharmacodynamics, and preliminary clinical efficacy of INCB106385 when given as monotherapy or in combination with INCMGA00012 in participants with selected CD8 T-cell-positive advanced solid tumors including SCCHN, NSCLC, ovarian cancer, CRPC, TNBC, bladder …

cancer of the ovary
cancer
bladder tumor
measurable disease
  • 17 views
  • 11 Jul, 2022
  • 19 locations
Featured trial
If you are dealing with overactive bladder (OAB) symptoms you may be eligible to participate in a research study for OAB.

If you are dealing with overactive bladder (OAB) symptoms you may be eligible to participate in a research study for OAB.

  • 286 views
  • 08 Nov, 2020
  • 1 location
Featured trial
SYNERGY

SYNERGY

  • 99 views
  • 08 Nov, 2020
  • 1 location
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)

The purpose of this study is to evaluate the efficacy of mirabegron in children (5 to < 12 years of age) with OAB. This study will also evaluate the safety and tolerability of mirabegron in pediatric participants with OAB and evaluate the pharmacokinetics after multiple dose administration of mirabegron in …

incontinence
mirabegron
  • 9 views
  • 08 Aug, 2022
  • 27 locations
A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder.

solifenacin
  • 1 views
  • 19 Jun, 2022
  • 1 location
InterStim Micro Post Market Clinical Follow-up Study (ELITE)

Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.

incontinence
neuromodulation
  • 0 views
  • 30 Jun, 2022
  • 27 locations
A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab (Cohort 1), or TAR-200 alone (Cohort 2), or cetrelimab alone (Cohort 3) with Carcinoma in Situ (CIS), with or without concomitant high-grade Ta or T1 papillary disease.

cystoscopy
carcinoma
radical cystectomy
bladder tumor
intravesical bcg
  • 11 views
  • 21 Jul, 2022
  • 100 locations
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (SunRISe-2)

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy.

neutrophil count
radical cystectomy
bladder tumor
gemcitabine
conjugated bilirubin
  • 66 views
  • 30 Apr, 2022
  • 127 locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

bladder tumor
gemcitabine
mitomycin
metastatic bladder carcinoma
pembrolizumab
  • 78 views
  • 11 Aug, 2022
  • 99 locations
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

The purpose of this study is to evaluate recurrence-free survival (RFS) in participants treated with erdafitinib vs Investigator's Choice, for participants with high-risk non-muscle-invasive bladder cancer (NMIBC) who harbor fibroblast growth factor receptor (FGFR) mutations or fusions, and who recurred after bacillus calmette-guerin (BCG) therapy.

carcinoma
bladder tumor
gemcitabine
bcg vaccine
mitomycin
  • 0 views
  • 27 Jul, 2022
  • 144 locations